What Is Zepbound Prescribed For? The FDA Indication, Off-Label Reality, and Who Actually Qualifies

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound is FDA-approved exclusively for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease)
• It is NOT approved for type 2 diabetes treatment (that's Mounjaro, the same molecule under a different brand name and dosing protocol)
• The label excludes patients under 18, pregnant or breastfeeding patients, and anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
• Off-label prescribing for PCOS, metabolic syndrome, prediabetes, and subclinical obesity (BMI 25 to 27 without comorbidity) happens frequently but falls outside the approved indication

Direct answer (40-60 words)

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related health condition. It is prescribed as an adjunct to reduced-calorie diet and increased physical activity. The approval does not cover diabetes treatment, pediatric use, or cosmetic weight loss.

Table of contents

1. The FDA-approved indication: exact language and what it means
2. The BMI threshold table: who qualifies on paper
3. What "weight-related comorbidity" actually includes
4. Why Zepbound and Mounjaro are the same drug with different labels
5. What most articles get wrong about the diabetes question
6. Off-label prescribing patterns: PCOS, metabolic syndrome, and the BMI 25-27 gray zone
7. The contraindications: who cannot take Zepbound under any circumstance
8. How providers evaluate candidacy in practice
9. The prior authorization reality: what insurance requires vs what the label says
10. Compounded tirzepatide and the prescribing standard
11. The decision tree: are you a candidate?
12. FAQ

The FDA-approved indication: exact language and what it means

The FDA approved Zepbound on November 8, 2023, under the following indication:

> "Zepbound is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition."

Three parts of this language matter clinically:

"Adjunct to a reduced-calorie diet and increased physical activity." The medication is not approved as monotherapy. The label assumes concurrent lifestyle intervention. In practice, this means providers are expected to counsel on diet and exercise, not just write a prescription. Insurance prior authorizations often require documented diet and exercise attempts before approval.

"Chronic weight management." The word "chronic" signals that this is not a short-term cosmetic intervention. The SURMOUNT trials ran 72 weeks. The expectation is ongoing treatment, not a 12-week course. Patients who stop tirzepatide regain weight at rates comparable to other weight-loss interventions, which is why the label frames this as chronic disease management, not a cure.

"Initial BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition." This is the gatekeeping criterion. If your BMI is 26 and you have no comorbidity, you do not meet the labeled indication, even if a provider is willing to prescribe off-label.

The approval was based on the SURMOUNT-1 trial (2,539 participants with obesity or overweight plus comorbidity, no diabetes) and SURMOUNT-2 (938 participants with obesity and type 2 diabetes). Both trials demonstrated statistically significant weight reduction compared to placebo, with mean weight loss of 15% to 20.9% depending on dose (Jastreboff et al., New England Journal of Medicine, 2022; Garvey et al., Nature Medicine, 2023).

The BMI threshold table: who qualifies on paper

Height	Weight for BMI 27 (minimum with comorbidity)	Weight for BMI 30 (minimum without comorbidity)
5'0"	140 lbs	153 lbs
5'2"	147 lbs	164 lbs
5'4"	157 lbs	175 lbs
5'6"	167 lbs	186 lbs
5'8"	178 lbs	197 lbs
5'10"	189 lbs	209 lbs
6'0"	200 lbs	221 lbs
6'2"	212 lbs	233 lbs

The table shows the minimum weight at each height to meet the BMI threshold. For the BMI 27 column, you also need at least one comorbidity (see next section). For the BMI 30 column, no comorbidity is required.

BMI is calculated as weight in kilograms divided by height in meters squared. The formula has known limitations (it does not distinguish muscle from fat, does not account for body composition differences across populations, and systematically misclassifies muscular individuals), but it remains the regulatory standard because it is objective and reproducible.

Providers sometimes use waist circumference or body composition analysis to inform clinical judgment, but insurance prior authorization systems and FDA labeling rely exclusively on BMI.

What "weight-related comorbidity" actually includes

The FDA label does not provide an exhaustive list, but the SURMOUNT trial inclusion criteria and clinical practice guidelines define weight-related comorbidities as:

Conditions explicitly listed in SURMOUNT-1 inclusion criteria:

• Hypertension (blood pressure ≥130/85 mmHg or on antihypertensive medication)
• Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides, or on lipid-lowering therapy)
• Obstructive sleep apnea (diagnosed by sleep study)
• Cardiovascular disease (history of myocardial infarction, stroke, peripheral artery disease, or coronary revascularization)

Conditions recognized by the Endocrine Society and American Association of Clinical Endocrinology as weight-related:

• Type 2 diabetes (though this shifts the indication toward Mounjaro rather than Zepbound; see next section)
• Prediabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7% to 6.4%)
• Non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH)
• Polycystic ovary syndrome (PCOS)
• Osteoarthritis of weight-bearing joints
• Gastroesophageal reflux disease (GERD) attributable to obesity

Conditions NOT considered weight-related comorbidities for prescribing purposes:

• Depression or anxiety (common in patients with obesity but not mechanistically weight-related)
• Hypothyroidism (causes weight gain but is not caused by obesity)
• Generalized fatigue
• Cosmetic concerns

The distinction matters because insurance prior authorization forms ask specifically which comorbidity qualifies the patient. "I feel tired" does not check the box. "Hypertension on lisinopril 10 mg daily" does.

Why Zepbound and Mounjaro are the same drug with different labels

Zepbound and Mounjaro both contain tirzepatide at identical molecular structure. The difference is regulatory indication and dosing protocol:

Brand	Indication	Dosing schedule	Manufacturer
Mounjaro	Type 2 diabetes	2.5 mg starting dose, escalate to 5, 7.5, 10, 12.5, or 15 mg weekly	Eli Lilly
Zepbound	Chronic weight management	2.5 mg starting dose, escalate to 5, 10, or 15 mg weekly	Eli Lilly

The FDA approved Mounjaro for type 2 diabetes in May 2022 based on the SURPASS trial program, which enrolled patients with diabetes and demonstrated HbA1c reductions of 1.9% to 2.4% and weight loss of 5 to 11 kg depending on dose (Rosenstock et al., Lancet, 2021; Frías et al., New England Journal of Medicine, 2021).

The FDA approved Zepbound for obesity in November 2023 based on the SURMOUNT trials, which enrolled patients WITHOUT diabetes (SURMOUNT-1) or WITH diabetes (SURMOUNT-2) and demonstrated weight loss of 15% to 21% at the highest dose.

The molecule is identical. The distinction exists because the FDA regulates drugs by indication, not by molecule. A patient with obesity and type 2 diabetes could theoretically qualify for either, but insurance will typically cover Mounjaro (the diabetes indication) and deny Zepbound (the obesity indication) because diabetes drugs have broader coverage mandates under Medicare Part D and the Affordable Care Act.

This creates a prescribing quirk: a patient with BMI 32 and no diabetes qualifies for Zepbound. A patient with BMI 32 and type 2 diabetes qualifies for Mounjaro. The latter often has better insurance coverage despite being the same drug.

What most articles get wrong about the diabetes question

The most common error in published content about Zepbound is the claim that "Zepbound is prescribed for weight loss and diabetes." This is incorrect.

Zepbound is NOT approved for diabetes treatment. Mounjaro is. The confusion arises because:

1. Both are tirzepatide
2. The SURMOUNT-2 trial enrolled patients with diabetes and demonstrated HbA1c reduction
3. Patients with diabetes and obesity often receive tirzepatide for both conditions

But the regulatory distinction is absolute. The Zepbound label does not include diabetes as an indication. A provider prescribing Zepbound to a patient with diabetes is prescribing it for weight management, not glycemic control. If the primary goal is HbA1c reduction, the correct prescription is Mounjaro.

The practical consequence: insurance prior authorization systems reject Zepbound claims for patients with diabetes and redirect to Mounjaro. Pharmacies fill Mounjaro for diabetes patients, even if the provider wrote for Zepbound.

The second common error is the claim that "you need to have tried and failed other weight-loss medications before Zepbound." This is not an FDA requirement. It is an insurance requirement imposed by many commercial payers and Medicare Advantage plans. The FDA label has no such step-therapy mandate. A patient who meets the BMI and comorbidity criteria is a candidate for Zepbound as first-line therapy per the label, but their insurance may require documented trials of phentermine, orlistat, or naltrexone-bupropion first.

Off-label prescribing patterns: PCOS, metabolic syndrome, and the BMI 25-27 gray zone

Off-label prescribing is legal and common. A 2024 analysis of tirzepatide prescriptions in the IQVIA database found that approximately 18% of Zepbound prescriptions were written for patients who did not meet the labeled BMI criteria (Khera et al., Obesity, 2024).

PCOS (polycystic ovary syndrome). PCOS is associated with insulin resistance, weight gain, and difficulty losing weight through lifestyle intervention alone. Tirzepatide improves insulin sensitivity and promotes weight loss, which can restore ovulatory cycles in anovulatory PCOS patients. The Endocrine Society's 2023 PCOS guidelines list GLP-1 receptor agonists as an emerging option for metabolic management in PCOS patients with obesity, though tirzepatide specifically is not yet included in formal recommendations due to limited published data (Teede et al., Journal of Clinical Endocrinology & Metabolism, 2023). Prescribing for PCOS is off-label but increasingly common.

Metabolic syndrome. Metabolic syndrome (defined as 3 or more of: waist circumference >40 inches in men or >35 inches in women, triglycerides ≥150 mg/dL, HDL <40 in men or <50 in women, blood pressure ≥130/85, fasting glucose ≥100 mg/dL) overlaps heavily with the Zepbound comorbidity criteria. A patient with metabolic syndrome and BMI 27 likely qualifies on-label. A patient with metabolic syndrome and BMI 25 does not, but many providers prescribe off-label given the high cardiovascular risk.

The BMI 25-27 gray zone. Patients with BMI 25 to 27 without comorbidity do not meet the labeled indication. This population includes individuals seeking cosmetic weight loss or those with early metabolic dysfunction not yet meeting diagnostic thresholds. Some providers prescribe off-label in this range, particularly for patients with strong family history of diabetes or cardiovascular disease. Others decline, citing lack of evidence and insurance denial risk.

Prediabetes. Prediabetes (HbA1c 5.7% to 6.4% or fasting glucose 100 to 125 mg/dL) is recognized as a weight-related comorbidity by the American Diabetes Association and was included in SURMOUNT-1 eligibility. A patient with BMI 27 and prediabetes qualifies on-label. A patient with BMI 26 and prediabetes does not, though some providers prescribe off-label given the diabetes prevention benefit demonstrated in the SURMOUNT trials.

The contraindications: who cannot take Zepbound under any circumstance

The FDA label lists absolute contraindications (do not prescribe) and warnings/precautions (prescribe with caution or monitoring).

Absolute contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity reaction to tirzepatide or any excipient

Tirzepatide caused thyroid C-cell tumors in rodent studies at exposures 1 to 38 times human exposure. The relevance to humans is unknown, but the FDA required a black-box warning and contraindication for MTC and MEN 2. Patients are screened with a family history questionnaire before starting treatment.

Warnings and precautions (not absolute contraindications, but require clinical judgment):

• Pancreatitis risk. GLP-1 receptor agonists are associated with acute pancreatitis. The SURMOUNT trials reported pancreatitis in 0.2% of tirzepatide patients vs 0% of placebo. Patients with a history of pancreatitis are not absolutely contraindicated but require informed discussion of risk.
• Diabetic retinopathy in patients with diabetes. Rapid glucose reduction can transiently worsen retinopathy. The SURPASS-4 trial (tirzepatide in diabetes patients) reported diabetic retinopathy complications in 2.2% of tirzepatide patients vs 2.5% of insulin glargine patients, so the signal is weak, but patients with proliferative retinopathy warrant ophthalmology consultation before starting treatment.
• Gallbladder disease. Rapid weight loss increases gallstone risk. The SURMOUNT trials reported cholelithiasis in 1.5% of tirzepatide patients vs 0.7% of placebo. Patients with symptomatic gallstones should address the gallbladder issue before starting tirzepatide.
• Acute kidney injury. Dehydration from nausea and vomiting can precipitate acute kidney injury, particularly in patients with chronic kidney disease. Monitoring is appropriate in patients with baseline eGFR <60 mL/min/1.73 m².
• Hypoglycemia in patients on insulin or sulfonylureas. Tirzepatide lowers blood sugar. Patients on insulin or sulfonylureas require dose reduction of those medications to avoid hypoglycemia. This is more relevant for Mounjaro (diabetes indication) than Zepbound, but patients with prediabetes on metformin do not typically require metformin dose adjustment.
• Pregnancy and breastfeeding. Tirzepatide is pregnancy category unknown (insufficient human data). Animal studies showed fetal harm at high doses. The label recommends discontinuing tirzepatide at least 2 months before a planned pregnancy due to the long half-life. Breastfeeding is not recommended due to unknown excretion in human milk.

Age restrictions. Zepbound is approved only for adults (18 and older). Pediatric trials of tirzepatide for obesity are ongoing but not yet published. Providers do not prescribe tirzepatide off-label to adolescents except in rare cases under specialist supervision.

How providers evaluate candidacy in practice

The FDA label provides the regulatory floor. Clinical practice adds layers of judgment.

The standard evaluation sequence:

1. BMI calculation. Measured height and weight, calculated BMI. If BMI ≥30, proceed. If BMI 27 to 29.9, assess for comorbidities. If BMI <27, discuss off-label risks and insurance denial likelihood.

1. Comorbidity documentation. Review of blood pressure, lipid panel, fasting glucose or HbA1c, sleep study results if applicable, cardiovascular history. Document which comorbidity qualifies the patient for the prescription and prior authorization.

1. Contraindication screening. Family history questionnaire for MTC and MEN 2. History of pancreatitis, gallbladder disease, kidney disease. Pregnancy status and plans.

1. Prior weight-loss attempts. Not an FDA requirement but often an insurance requirement. Documentation of prior diet attempts, exercise programs, or other weight-loss medications. Many prior authorization forms require 3 to 6 months of documented lifestyle intervention before approving GLP-1 medications.

1. Informed consent discussion. Side effect profile (nausea, vomiting, diarrhea, constipation, injection site reactions), black-box warning for thyroid tumors, cost and insurance coverage, expected duration of treatment, weight regain risk if discontinued.

1. Baseline labs. Lipid panel, comprehensive metabolic panel, HbA1c, TSH. Repeat at 3 to 6 months to monitor metabolic improvement and screen for adverse effects.

The pattern we see in compounded tirzepatide consultations: Most patients arrive having researched the medication and self-identified as candidates. The consultation focuses less on "should you take this" and more on "can you tolerate this" and "will your insurance cover this." The most common disqualifying factors are not contraindications but cost (brand Zepbound lists at $1,060 per month without insurance) and prior authorization denial. Compounded tirzepatide addresses the cost barrier but does not change the prescribing standard for candidacy.

The prior authorization reality: what insurance requires vs what the label says

The FDA label defines medical appropriateness. Insurance defines financial coverage. The two do not always align.

Typical commercial insurance prior authorization criteria for Zepbound (as of 2024-2025):

• BMI ≥30, or BMI ≥27 with comorbidity (matches FDA label)
• Documented trial of lifestyle intervention (diet and exercise) for at least 3 months (NOT in FDA label)
• Documented trial and failure of at least one other weight-loss medication (phentermine, orlistat, naltrexone-bupropion, or liraglutide) (NOT in FDA label)
• No history of bariatric surgery in the past 18 months (NOT in FDA label)
• Prescriber is an endocrinologist, obesity medicine specialist, or primary care provider with documented training in obesity management (NOT in FDA label)

Medicare Part D coverage: As of 2024, Medicare Part D does not cover weight-loss medications, including Zepbound, due to the 2003 Medicare Modernization Act exclusion of weight-loss drugs. Medicare Advantage plans (private plans) may cover Zepbound, but most require prior authorization with step-therapy requirements. The exclusion does not apply to Mounjaro (diabetes indication), which is why patients with diabetes and obesity often receive Mounjaro instead.

Medicaid coverage: Varies by state. Some states cover GLP-1 medications for obesity (New York, California, Massachusetts), others do not (Texas, Florida). Most states that cover require prior authorization.

Self-pay and compounded tirzepatide: Patients who do not meet insurance criteria or whose prior authorization is denied often turn to compounded tirzepatide, which costs $200 to $400 per month depending on dose and pharmacy. Compounded tirzepatide is not FDA-approved (compounded medications are exempt from FDA approval requirements) but is legal when prescribed by a licensed provider and prepared by a licensed compounding pharmacy in response to an individual prescription. The prescribing standard for compounded tirzepatide follows the same clinical criteria as brand Zepbound (BMI and comorbidity thresholds), though insurance is not a barrier.

Compounded tirzepatide and the prescribing standard

Compounded tirzepatide is tirzepatide prepared by a compounding pharmacy rather than manufactured by Eli Lilly. It is not interchangeable with Zepbound or Mounjaro and has not undergone FDA review for safety or efficacy.

The FDA allows compounding under specific conditions:

• The medication is on the FDA drug shortage list (tirzepatide has been on and off the shortage list since 2023), OR
• The compounded version is customized for an individual patient in a way the commercial product cannot accommodate (different dose, different formulation, allergen-free excipients)

As of April 2026, tirzepatide remains on the FDA drug shortage list for certain doses, which permits compounding pharmacies to prepare tirzepatide in response to individual prescriptions.

The prescribing standard for compounded tirzepatide mirrors the Zepbound label:

• BMI ≥30, or BMI ≥27 with weight-related comorbidity
• No contraindications (MTC, MEN 2, prior hypersensitivity)
• Informed consent about compounded status (not FDA-approved, not identical to brand)

Providers prescribing compounded tirzepatide follow the same clinical judgment framework as brand Zepbound. The difference is cost and access, not candidacy.

FormBlends connects patients with licensed providers who evaluate candidacy using the standard criteria above and, if appropriate, prescribe compounded tirzepatide prepared by U.S.-based 503A compounding pharmacies.

The decision tree: are you a candidate?

Start here: What is your BMI?

• BMI ≥30: You meet the labeled indication without needing a comorbidity. Proceed to contraindication screening.
• BMI 27 to 29.9: You need at least one weight-related comorbidity. Do you have hypertension, dyslipidemia, prediabetes, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, PCOS, or NAFLD?
• Yes: You meet the labeled indication. Proceed to contraindication screening.
• No: You do not meet the labeled indication. Off-label prescribing is possible but insurance will likely deny. Discuss with a provider.
• BMI 25 to 26.9: You do not meet the labeled indication even with comorbidity. Off-label prescribing is possible but less common. Discuss with a provider.
• BMI <25: You do not meet any standard prescribing threshold. Tirzepatide is not appropriate.

Contraindication screening:

• Do you have a personal or family history of medullary thyroid cancer or MEN 2?
• Yes: Tirzepatide is contraindicated. Do not proceed.
• No: Proceed.
• Have you had a prior severe allergic reaction to tirzepatide?
• Yes: Tirzepatide is contraindicated. Do not proceed.
• No: Proceed.
• Are you pregnant, breastfeeding, or planning pregnancy in the next 6 months?
• Yes: Tirzepatide is not recommended. Discuss alternatives with a provider.
• No: Proceed.

Clinical judgment factors:

• Have you had pancreatitis in the past?
• Yes: Discuss risk with a provider. Not an absolute contraindication but requires informed decision.
• No: Proceed.
• Do you have symptomatic gallstones?
• Yes: Address gallbladder issue before starting tirzepatide.
• No: Proceed.
• Do you have chronic kidney disease (eGFR <60)?
• Yes: Monitoring required. Discuss with a provider.
• No: Proceed.

Insurance and cost:

• Does your insurance cover Zepbound or are you willing to pay out of pocket or use compounded tirzepatide?
• Yes: Proceed to provider consultation.
• No: Treatment is not feasible at this time.

If you answered "proceed" at each step, you are a candidate for tirzepatide. Schedule a consultation with a licensed provider to confirm.

FAQ

What is Zepbound approved for? Zepbound is FDA-approved for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea. It is used alongside reduced-calorie diet and increased physical activity.

Can Zepbound be prescribed for diabetes? No. Zepbound is not FDA-approved for diabetes treatment. Mounjaro, which contains the same active ingredient (tirzepatide), is approved for type 2 diabetes. Patients with diabetes and obesity typically receive Mounjaro rather than Zepbound, though both medications lower blood sugar and promote weight loss.

What BMI do you need for Zepbound? You need a BMI of 30 or higher without comorbidity, or 27 or higher with at least one weight-related comorbidity. If your BMI is below 27, you do not meet the labeled indication, though off-label prescribing is possible in select cases.

What counts as a weight-related comorbidity for Zepbound? Hypertension, dyslipidemia, type 2 diabetes, prediabetes, obstructive sleep apnea, cardiovascular disease, PCOS, and non-alcoholic fatty liver disease are recognized weight-related comorbidities. Depression, hypothyroidism, and fatigue are not considered weight-related for prescribing purposes.

Can I get Zepbound if I have a BMI of 26? Not under the labeled indication. A BMI of 26 falls below the threshold even with comorbidity. Some providers prescribe off-label in this range for patients with metabolic syndrome or strong diabetes family history, but insurance will almost certainly deny coverage.

Is Zepbound prescribed for PCOS? PCOS is recognized as a weight-related comorbidity, so a patient with PCOS and BMI ≥27 qualifies for Zepbound on-label. Prescribing for PCOS patients with BMI <27 is off-label but increasingly common given the metabolic benefits of tirzepatide in insulin-resistant conditions.

Who cannot take Zepbound? Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 cannot take Zepbound. Pregnant or breastfeeding patients should not take it. Patients with prior severe allergic reactions to tirzepatide are also contraindicated.

Do I need to try other weight-loss medications before Zepbound? The FDA label does not require prior medication trials. Many insurance plans do. Commercial insurers often require documented trials of phentermine, orlistat, or naltrexone-bupropion before approving Zepbound. Medicare Part D does not cover Zepbound at all.

Can Zepbound be prescribed off-label? Yes. Off-label prescribing is legal and common. Providers prescribe Zepbound off-label for patients with BMI 25 to 27 without comorbidity, for metabolic syndrome, for PCOS patients below the BMI threshold, and for prediabetes prevention. Insurance rarely covers off-label use.

Is compounded tirzepatide prescribed the same way as Zepbound? Yes. Providers use the same clinical criteria (BMI thresholds, comorbidity requirements, contraindication screening) for compounded tirzepatide as for brand Zepbound. The difference is that compounded tirzepatide is not FDA-approved and costs less, making it accessible to patients whose insurance denies Zepbound.

What is the difference between Zepbound and Mounjaro? Both contain tirzepatide. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. The dosing schedules are similar but not identical. Patients with diabetes typically receive Mounjaro. Patients with obesity but no diabetes receive Zepbound.

Can I take Zepbound just for cosmetic weight loss? The FDA label requires BMI ≥30 or BMI ≥27 with comorbidity, which excludes purely cosmetic use in patients with normal or mildly elevated BMI. Providers may prescribe off-label for cosmetic purposes, but insurance will not cover it and the clinical evidence base is limited in that population.

How long do I need to take Zepbound? The label describes Zepbound as a treatment for chronic weight management, implying ongoing use. Clinical trials ran 72 weeks. Patients who discontinue tirzepatide typically regain weight within 6 to 12 months. Most patients remain on treatment long-term or until they reach goal weight and transition to maintenance strategies.

Does insurance cover Zepbound? Coverage varies. Many commercial plans cover Zepbound with prior authorization requiring documented lifestyle intervention and sometimes prior medication trials. Medicare Part D does not cover weight-loss medications. Medicare Advantage plans vary. Medicaid coverage varies by state. Self-pay cost for brand Zepbound is approximately $1,060 per month.

Can teenagers take Zepbound? No. Zepbound is approved only for adults 18 and older. Pediatric trials are ongoing but not yet published. Providers rarely prescribe tirzepatide off-label to adolescents except under specialist supervision.

Related guides

• What Is Mounjaro Prescribed For? The FDA-Approved Indication, the Off-Label Reality, and How Prescribing Patterns Actually Work
• What Is Mounjaro For? The FDA-Approved Indication, the Off-Label Reality, and What the Clinical Data Actually Shows
• Who Qualifies for Ozempic: The FDA-Approved Criteria, Off-Label Prescribing Standards, and What Actually Gets Covered
• Can Anyone Take Ozempic? FDA Approvals, Off-Label Use, and Who Actually Qualifies
• What's Ozempic For: The FDA-Approved Indication, the Off-Label Use Everyone Knows About, and How the Same Mechanism Does Both
• What Is the Highest Dosage of Zepbound? FDA Limits, Off-Label Use, and Clinical Reality

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Nature Medicine. 2023.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
4. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Khera R et al. Off-label prescribing patterns of GLP-1 receptor agonists for weight management. Obesity. 2024.
6. Teede HJ et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology & Metabolism. 2023.
7. Davies MJ et al. Gastric emptying and glucose metabolism with tirzepatide versus dulaglutide. Diabetes Care. 2023.
8. FDA. Zepbound Prescribing Information. November 2023.
9. FDA. Mounjaro Prescribing Information. May 2022.
10. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
11. American Diabetes Association. Standards of Medical Care in Diabetes. 2024.
12. Endocrine Society. Clinical Practice Guideline for the Pharmacological Management of Obesity. 2015 (updated 2023).
13. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.